Newborn screening for tyrosinemia type I: Further evidence that succinylacetone determination on blood spot is essential

Journal of Inherited Metabolic Disease

Volumn 1, Issue , 2011, Pages 107-109

  La Marca, Giancarlo ^a,b   Malvagia, Sabrina ^a   Pasquini, Elisabetta ^a   Cavicchi, Catia ^a   Morrone, Amelia ^a,b   Ciani, Federica ^a   Funghini, Silvia ^a   Villanelli, Fabio ^a   Zammarchi, Enrico ^b   Guerrini, Renzo ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Newborn screening; Succynilacetone; Tyrosinemiatype I

Indexed keywords

EID: 84920916719     PISSN: 01418955     EISSN: 15732665     Source Type: Journal    
DOI: 10.1007/8904_2011_24     Document Type: Article

References (17)

1. Adam BW, Lim TH, Hall EM, Hannon WH (2009) Preliminary proficiency testing results for succinylacetone in dried blood spots for newborn screening for tyrosinemia type I. ClinChem 55:2207–2213
2. Al-Dirbashi OY, Rashed MS, Jacob M, Al-Ahaideb LY, Al-Amoudi M, Rahbeeni Z, Al-Sayed MM et al (2008) Improved method to determinesuccinylacetone in dried blood spots for diagnosis of tyrosinemia type I using UPLC-MS/MS. Biomed Chromatogr 22:1181–1185
3. Al-Gazali L, Hamamy H, Al-Arrayad S (2006) Genetic disorders in theArab world. BMJ 333:831–834
4. Allard P, Grenier A, Korson MS, Zytkovicz TH (2004) Newborn screening for hepatorenaltyrosinemia by tandem mass spectrometry: analysis of succinylacetone extracted from dried blood spots. Clin Biochem 37:1010–1015
5. Arranz JA, Pinol F, Kozak L, Perez-Cerda C, Cormand B, Ugarte M, Riudor E (2002) Splicing mutations, mainly IVS6–1(G>T), accountfor 70% of fumarylacetoacetate hydrolase (FAH) gene alterations,including 7 novel mutations, in a survey of 29 tyrosinemia type Ipatients. Hum Mutat 20:180–188
6. Jaouad IC, Elalaoui SC, Sbiti A, Elkerh F, Belmahi L, Sefiani A (2009) Consanguineous marriages in Morocco and the consequence for the incidence of autosomal recessive disorders. J Biosoc Sci 41:575–581
7. Joshi SN, Venugopalan P (2004) Experience with NTBC therapy inhereditary tyrosinemia type I: an alternative to liver transplantation. Ann Trop Paediatr 24:259–265
8. la Marca G, Malvagia S, Pasquini E, Innocenti M, Fernandez MR, Donati MA, Zammarchi E (2008) The inclusion of succinylacetoneas marker for tyrosinemia type I in expanded newborn screening programs. Rapid Commun Mass Spectrom 22:812–818
9. la Marca G, Malvagia S, Funghini S, Pasquini E, Moneti G, Guerrini R, Zammarchi E (2009) The successful inclusion of succinylacetone asa marker of tyrosinemia type I in Tuscany newborn screening program. Rapid Commun Mass Spectrom 23:3891–3893
10. Lindstedt S, Holme E, Lock EA, Hjalmarson O, Strandvik B (1992) Treatment of hereditary tyrosinemia type I by inhibition of 4-hydroxyphenylpyruvatedioxygenase. Lancet 340:813–817
11. Mitchell GA, Grope M, Lambert M, Tanguay RM (2001) Hypertyrosinemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) Themetabolic and molecular bases of inherited disease. McGraw-Hill, New York, pp 1777–1805
12. Ploos van Amstel JK, Bergman AJ, van Beurden EA, Roijers JF, Peelen T, van den Berg IE, Poll-The BT, Kvittingen EA, Berger R (1996) Hereditary tyrosinemia type 1: novel missense, nonsense and splice consensus mutations in the human fumarylaceto acetatehydrolase gene; variability of the genotypephenotype relationship. Hum Genet 97:51–59
13. Rootwelt H, Høie K, Berger R, Kvittingen EA (1996) Fumarylacetoacetase mutations in tyrosinaemia type I. Hum Mutat 7:239–243
14. Sander J, Janzen N, Peter M, Sander S, Steuerwald U, Holtkamp U, Schwahn B et al (2006) Newborn screening for hepatorenaltyrosinemia:tandem mass spectrometric quantification of succinylacetone. ClinChem 52:482–487
15. Turgeon C, Magera MJ, Allard P, Tortorelli S, Gavrilov D, Oglesbee D, Raymond K et al (2008) Combined newborn screening for succinylacetone, amino acids, and acylcarnitines in dried blood spots. ClinChem 54:657–664
16. US Department of Health and Human Services, Maternal and Child Health Bureau (2005) Newborn screening: toward a uniform screening panel and system report for public comment. Fed Regist 70:308–329
17. Wilcken B, Wiley V, Hammond J, Carpenter K (2003) Screening newborns for inborn errors of metabolism by tandem mass spectrometry. N Engl J Med 348:2304–2312